<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">2912</id>
  <title>T3D2870</title>
  <common-name>Trimipramine</common-name>
  <description>Trimipramine is only found in individuals that have used or taken this drug. It is a tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]Trimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).</description>
  <cas>739-71-9</cas>
  <pubchem-id>5584</pubchem-id>
  <chemical-formula>C20H26N2</chemical-formula>
  <weight>294.209600</weight>
  <appearance>White powder.</appearance>
  <melting-point>45°C</melting-point>
  <boiling-point nil="true"/>
  <density nil="true"/>
  <solubility>Slightly soluble</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Oral. Rapid absorption</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>Trimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).</mechanism-of-toxicity>
  <metabolism>HepaticHalf Life: 11-18 hrs</metabolism>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance</use-source>
  <min-risk-level nil="true"/>
  <health-effects nil="true"/>
  <symptoms>Side effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting</symptoms>
  <treatment>Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. (L1712)</treatment>
  <created-at type="dateTime">2009-07-21T20:27:30Z</created-at>
  <updated-at type="dateTime">2014-12-24T20:25:52Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Trimipramine</wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id>C14029</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>9738</chebi-id>
  <biocyc-id></biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id>Trimipramine</stitch-id>
  <drugbank-id>DB00726</drugbank-id>
  <pdb-id></pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12</moldb-smiles>
  <moldb-formula>C20H26N2</moldb-formula>
  <moldb-inchi>InChI=1/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3</moldb-inchi>
  <moldb-inchikey>InChIKey=ZSCDBOWYZJWBIY-UHFFFAOYNA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">294.4338</moldb-average-mass>
  <moldb-mono-mass type="decimal">294.209598842</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp>4.2</logp>
  <hmdb-id>HMDB14864</hmdb-id>
  <chembl-id>CHEMBL644</chembl-id>
  <chemspider-id>5382</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference></synthesis-reference>
  <structure-image-caption nil="true"/>
</compound>
